west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "荨麻疹" 11 results
  • 西替利嗪滴剂治疗慢性荨麻疹近期疗效观察

    【摘要】 目的 观察西替利嗪滴剂治疗慢性荨麻疹的疗效。 方法 选择2011年4月-2011年8月间80例慢性荨麻疹患者为研究对象,试验组40例给予西替利嗪滴剂1次/d,10 mg/次;对照组40例给予氯雷他定1次/d,10 mg/d,均连续服用28 d。分别于用药后第7、28天随访,观察疗效和不良反应。 结果 试验组治疗7、28 d有效率分别为72.5%、87.5%,对照组有效率分别为67.5%、85.0%,两组比较差异无统计学意义(χ2=0.060,0.081;Pgt;0.05)。 结论 口服西替利嗪滴剂或氯雷他定10 mg/d治疗慢性荨麻疹疗效相似,但滴剂剂量调整更准确,在慢性荨麻疹缓解期的维持减量阶段应用更方便。

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • BCGpolysaccharide Nucleic Acid Combined with Runzao Antipruritic Capsule in Treating Chronic Urticaria

    目的:观察卡介菌多糖核酸联合润燥止痒胶囊治疗慢性荨麻疹的疗效。方法: 将2008年4月~2009年4月门诊就诊的86例慢性荨麻疹患者随机分成两组,治疗组44例采用卡介菌多糖核酸2 mL肌注,隔日1次,18次为1疗程;同时予口服润燥止痒胶囊4粒,3次/d,连续治疗36天;对照组42例单独口服润燥止痒胶囊,方法疗程同治疗组。结果: 治疗组有效率为90.91%,对照组为7143%。两组比较差异有显著性(Plt;005)。结论: 卡介菌多糖核酸联合润燥止痒胶囊治疗慢性荨麻疹疗效确切。

    Release date:2016-08-26 02:21 Export PDF Favorites Scan
  • Effectiveness and Safety of Chinese Angelica Decoction for Chronic Urticaria: A Systematic Review

    Objective To evaluate the effectiveness and safety of Chinese angelica decoction (CAD) versus conventional treatment (CT) for chronic urticaria (CU). Methods Systematic searches were conducted in PubMed, The Cochrane Library, SCI, EMbase, VIP, CNKI and CBM to collect randomized controlled trials (RCTs) on CAD treating CU from inception to July 2011. Two reviewers independently screened articles according to the inclusion and exclusion criteria, extracted data and evaluated the quality of the included studies. Then meta-analysis was performed using RevMan 5.0.2. Results A total of 11 RCTs involving 1081 patients were included. The results of meta-analysis demonstrated that compared with the CT group (antihistamine therapy), CAD seemed higher in the cure rate (OR=2.36, 95%CI 1.80 to 3.10, I2=22%, Plt;0.000 01), improvement rate (OR=4.56, 95%CI 2.65 to 7.87, I2=0%, Plt;0.000 01), and lower in the relapse rate at the third month after the treatment (OR=0.43, 95%CI 0.22 to 0.82, I2=0%, P=0.01). No study reported the quality of life and severe adverse reactions after CAD treatment. Conclusion Current evidence shows CAD may be superior to CT in treating CU patients. However, due to lack of enough high-quality studies, CAD has to be further studied by conducting more strictly-designed, multicenter, large-scale and double-blind RCTs.

    Release date:2016-09-07 10:58 Export PDF Favorites Scan
  • Efficacy and Safety of Desloratadine in Chronic Urticaria: A Systematic Review

    Objectives To evaluate the efficacy and safety of desloratadine in the patients with chronic urticaria(cu). Methods We searched PubMed, Blackwell, BIOSIS Preview, The Cochrane Library, VIP and CNKI electronically from January 1, 2000 to April, 2008. Relevant journals and conference proceedings were also handsearched. Randomized controlled trials (RCTs) and quasi-RCTs comparing desloratadine with other medicines in the patients with CIU were considered eligible. The quality of the included trials was assessed by the Jadad scale, and meta-analysis was conducted using RevMan 5.0 software. Results Nineteen trials involving 3,448 participants contributed to the meta-analysis. The results of the meta-analysis indicated that desloratadine showed similar effect on the improvement of signs and symptoms compared with loratadine RR 1.04 and 95%CI 0.99 to 1.09, mizolastine in RR 0.99 and 95%CI 0.92 to 1.07, cetirizine RR 1.05 and 95%CI 0.97 to 1.13 and terfenadine RR 1.10 and 95%CI 0.84 to 1.44. And desloratadine had similar safety to mizolastine RR 0.84 and 95%CI 0.45 to 1.58, ceririzine RR 0.67 and 95%CI 0.67 and 0.39 to 1.15 and terfenadine RR 0.44 and 95%CI 0.17 to 1.10. Desloratadine was safer than loratadine RR 0.74 and 95%CI 0.55 to 1.00. Conclusions Desloratadine, the active metabolite of loratadine, is an oral, once-daily, non-sedating antihistamine that is effective in the treatment of CIU. Desloratadine provides rapid and sustained relief of CIU symptoms.

    Release date:2016-09-07 02:10 Export PDF Favorites Scan
  • Health technology assessment of four non-sedating antihistamines for allergic diseases

    Objective This review compared clinical effectiveness, cardiac safety and economics of astemizole, loratadine, cetirizine and terfenadine to provide evidence for adjustment of Essential Drug List in China. Search strategy We searched Medline, Cochrane Library, Embase and Chinese Biomedical Database. Fourteen databases for drug safety and pharmaceutical economics were additionally searched. Selection Criteria Randomized controlled trials and systematic reviews, published in English and Chinese and comparing two or more of these four antihistamines for allergic rhinitis and urticaria were included for study of effectiveness. Non-randomized clinical trials were additionally included for economic evaluation. Cardiac safety studies of antihistamines for allergic diseases of any type were included. Quality Appraisal Jadad scale was primarily applied to randomized controlled trials. Allocation concealment and intention-to-treat analysis were also appraised. The QUOROM statement was applied to systematic reviews and meta-analysis. Data extraction and analyses For the study of effectiveness, composite data were primarily extracted and analyzed by fixed effect model. Sensitivity analysis was done to explore the heterogeneity. For the study of cardiac safety, cases of adverse drug reactions and death were summarized. Difference of occurrence rate in sex and age were analyzed if possible.Electrocardiography and clinical symptoms were summarized. Results No studies on economic evaluation were identified. 27 and 6 randomized controlled trials, including 3 227 participants, for allergic rhinitis and urticaria were identified. Cetirizine was superior to loratadine (n=709) in symptom score and onset of action, superior to terfenadine (n=645) in Quality of Life and superior to astemizole (n=498) in patient satisfaction and onset of action. 73 h-ADR cases were identified in astemizole, 27 cases in terfenadine, 1 case in loratadine and none in cetirizine. No deaths were identified. Combination of terfenadine plus grapefruit juice (n=l8), itraconazole (n=6), nefazodone (n=67), and loratadine administration concomitant with cemitidine (n=30) significantly prolonged QTc interval. Conclusions Cetirizine was superior to other three antihistamines in terms of clinical effectiveness and drug safety. Astemizole and terfenadine could cause significantly more cardiac-related adverse reactions than cetirizine and loratadine.

    Release date:2016-09-07 02:29 Export PDF Favorites Scan
  • 特应性皮炎与慢性荨麻疹患者血清白细胞介素-4的检测

    目的 了解特应性皮炎与慢性荨麻疹患者外周血白细胞介素-4的水平。 方法 采用双夹心酶联免疫吸附试验法(ELASA)对2010年5月-2012年6月皮肤科门诊及变态反应门诊收治的31例特应性皮炎患者与30例IgE介导慢性荨麻疹患者进行血清白细胞介素-4检测。 结果 特应性皮炎与慢性荨麻疹患者血清白细胞介素-4明显高于正常人对照组(P<0.001)。 结论 特应性皮炎与慢性荨麻疹患者存在循环白细胞介素-4水平明显异常。

    Release date:2016-09-07 02:37 Export PDF Favorites Scan
  • 盐酸氮卓斯汀治疗急性荨麻疹

    【摘要】目的 观察盐酸氮卓斯汀片口服治疗急性荨麻疹的疗效。方法 2007年10月-2008年11月,采用平行对照方法,共治疗134例急性荨麻疹患者。治疗组 68例口服氮卓斯汀2 mg,每日1次,对照组66例口服赛庚定4 mg,每日3次。急性荨麻疹疗程为14 d。结果 治疗组显效率为691%(47/68),有效率为838%(57/66);对照组显效率为439%(29/66),有效率为576%(38/66),两组差异有统计学意义(P<005)。结论 盐酸氮卓斯汀治疗急性荨麻疹有效。

    Release date:2016-09-08 09:31 Export PDF Favorites Scan
  • 罕见腹型荨麻疹伴高淀粉酶血症一例分析

    Release date: Export PDF Favorites Scan
  • Association between Mycoplasma Pneumonia Infection and Acute Urticaria: A Case-control Study

    ObjectiveTo investigate the relationship between mycoplasma pneumonia infection (MP) and acute urticaria (AU). MethodsFrom December 2011 to November 2012, in the department of clinical laboratory of the Lishui Central Hospital, the blood samples of 178 patients with acute urticaria (group AU) and 200 healthy volunteers (group C) who initially visited this hospital were collected to detect the MP-IgM+IgG+IgA antibody in the serum. The occurrence of positive MP antibody was recorded and the positive rate was calculated. ResultsCompared with group C, the incidence of positive MP was significantly increased in group AU (P < 0.01). ConclusionMycoplasma pneumoniae infection may be one of the causes of acute urticaria.

    Release date: Export PDF Favorites Scan
  • Association between Dehydroepiandrosterone-sulfate and Chronic Urticaria: A Meta-analysis

    ObjectiveTo systematically review the association between dehydroepiandrosterone-sulfate (DHEA-S) and chronic urticarial (CU). MethodsWe searched databases including The Cochrane Library (Issue 3, 2015), PubMed, EMbase, CBM, VIP, CNKI and WanFang Data from inception to January 2016, to collect case-control studies about the association between DHEA-S and CU. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was performed by using RevMan 5.3 software. ResultsA total of 8 papers involving 9 case-control studies were included. The results of meta-analysis showed that DHEA-S might be associated with CU (SMD=-0.93, 95%CI -1.35 to -0.50, P<0.000 01). Subgroup analysis by the difference of measuring methods, indicated that DHEA-S might be associated with CU (ECLIA: SMD=-0.75, 95% CI -1.08 to -0.42, P<0.000 01; ELISA: SMD=-0.59, 95% CI -0.87 to -0.31, P<0.000 1; EIA: SMD=-2. 70, 95% CI -3.30 to -2.10, P<0.000 01). Sensitivity analysis showed that our results were reliable and stable. ConclusionThe meta-analysis suggests that DHEA-S might be associated with CU. Due to the limited quality and quantity of included studies, more high quality studies are needed to verify the above conclusion.

    Release date:2016-10-26 01:44 Export PDF Favorites Scan
2 pages Previous 1 2 Next

Format

Content